HCN Oncology Year-in-Review: Lung CancerDecember 21, 2021 | Oncology Hematology/Oncology Immunotherapy Combo Fails to Boost Survival in Limited-Disease SCLC A randomized phase II trial has found that consolidation therapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) after chemoradiotherapy did not lead to better survival outcomes for patients with small cell lung cancer (SCLC). The study enrolled 222 patients with stage I-IIIB histologically or cytologically confirmed limited-disease SCLC, and adequate hematologic, renal, lung, and pulmonary function. The combination regimen yielded no improvement in overall survival, and grade 3 adverse events were approximately 2.5 times more common in the dual therapy group. Read full article Internal Medicine Negative Trials Close the Book on Once-Promising SCLC Drug A once-hopeful antibody-drug conjugate for small-cell lung cancer (SCLC) failed to demonstrate a survival benefit in two large, randomized studies, and was found to be mostly toxic. The negative trial results have led to the end of a drug that was considered a promising potential antidote to deadly SCLC. Read full article Internal Medicine Non-Small Cell Lung Cancer Treatment Regimens Bookmark this page – or download the information directly, if you prefer – to ensure you’re always connected to the latest and greatest information on the very best in NSCLC treatment regimens (NCCN Guidelines). Read full article Endocrinology, Diabetes, Metabolism Does Metformin Improve Outcomes in Nondiabetic, Unresectable Stage III NSCLC Treated with Chemoradiation? Publication: JAMA Oncology Objective: With NSCLC having relatively poor outcomes and the significant data supporting the use of metformin as an antineoplastic agent, the researchers wanted to compare overall or progression-free survival in chemoradiation alone vs. chemoradiation + metformin stage III NSCLC patients. Design: Randomized clinical trial, open-label, phase 2 study; 167 eligible patients Read full article Hematology/Oncology Sintilimab Plus Chemo Prolongs Survival in Advanced Non-Small Cell Lung Cancer The encouraging results of the phase 3 ORIENT-11 trial, which included 397 patients with previously untreated, locally advanced metastatic non-squamous NSCLC without sensitizing EGFR or ALK aberrations, were published in the Journal of Thoracic Oncology.